ATLASENSE BIOMED LTD.

ATLASense Biomed develops, produces, and markets the RAPHAEL platform™ - The next generation solution for Remote Health Surveillance. The RAPHAEL Platform improves patient outcomes by facilitating the early detection of many health conditions. The RAPHAEL's data is constantly produced by the PolyMonitor™, an ATLASense proprietary single chest-worn wireless non-invasive monitor. "ATLASense is the only one that developed a platform based on the PolyMonitor™, that has widespread application... s in pre, intra, and post-hospital settings. In addition, it is versatile enough that clinicians can remotely customize for each particular patient" Michael Lewis, M.D., Henry Ford Health System's chair of anesthesiology. "This technology not only has the potential to monitor a patient during an operation but throughout their entire journey in the hospital and even at home recovering" Scott Dulchavsky, M.D., Ph.D., CEO of Henry Ford Innovations. To avoid deterioration of COVID-19 and COPD patients and enable preventive care, ATLASense develops various predictive analytics' clinical applications. One of our flagship applications is a new bio-marker, the "Respiratory Insufficiency Index" score based on special proprietary sensors and data analysis, which can alert between 1 to 3 days before any other marker and on the first four stages respiratory deterioration. The platform's unique data source is specially developed PolyMonitor™, a reusable, wireless, chest-worn single small device, actually enables the replacement of dozens of expensive monitoring devices and costs less than a tenth of the cost-of-use. In fact, in the U.S., our service is fully covered by state insurance MEDICARE, enabling the healthcare providers to apply for various combinations of reimbursement codes. The ability to remotely control and multi-functionality allows medical service providers to make faster and better clinical decisions and generate multiple revenues and profits. The company's product won the 2020 global challenge competition of Henry Ford Health Systems in the U.S. and conducted two clinical studies both in hospitals in Israel and the U.S.More